An AMCP PA/UM LINK Group Webinar.

How are we doing as an industry as we strive to balance evidence, access, and consistency across coverage policies?   This webinar takes a deep dive into how UM practices vary across payers and how they’ve evolved from 2017–2025. Dr. James D. Chambers, PhD, MPharm, Professor at Tufts Medicine and Center for the Evaluation of Value and Risk in Health, will examine the evidence health plans cite in drug coverage policies and assess how payer criteria align with pivotal clinical trials—using cell and gene therapies as a real‑world case study.

If you haven’t had an opportunity to hear Dr Chambers- you won’t want to miss this!  And if you have, we know you have already registered!  

A Pre-Approval Information Exchange (PIE) Webinar, presented by Takeda Pharmaceuticals.

Narcolepsy Type 1 (NT1) is a rare, chronic neurologic disorder caused by loss of orexin (hypocretin) neurons and marked by excessive daytime sleepiness and cataplexy. Beyond the classic pentad, additional manifestations can affect many aspects of daily functioning. Existing treatments focus on symptom relief alone, as many treated patients report residual symptoms and ongoing impairment. These limitations underscore the need to investigate therapies that directly target orexin deficiency in NT1.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Precision Medicine LINK Webinar.

The next Precision Medicine LINK webinar brings standards, advocacy, and real‑world insights together to help you create clearer, more consistent pathways to precision medicine access!

The session opens with Melissa Y. Tjota, MD, PhD, with the University of Chicago Medicine, who will walk through recommended terms and definitions from the 2025 NCCN Biomarkers Resource Committee, helping ground coverage and utilization decisions in a shared, consistent language. Hilary Gee Goeckner, MSW of the American Cancer Society Cancer Action Network will then highlight ongoing advocacy efforts shaping access to care across the country. Finally, Pam Pawloski, PharmD, Principal Research Scientist with ARI,  will share insights from a LUNGevity‑ and ACS CAN‑funded real‑world study exploring payer‑identified gaps and opportunities in coverage for broad molecular testing.

Let’s dig into it together—join the Precision Medicine LINK conversation.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Takeda Oncology.

AMCP and Takeda Oncology are pleased to invite you to a PIE webinar on rusfertide, an investigational, first-in-class hepcidin mimetic being studied for the treatment of polycythemia vera (PV)-a chronic blood cancer characterized by the overproduction of red blood cells. We'll review the unmet need, key clinical data, and anticipated product profile, followed by a brief Q&A. We look forward to your participation.

This webinar is offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Otsuka Pharmaceutical Development & Commercialization, Inc.

ADHD is a complex neurodevelopmental disorder encompassing broad symptoms. Current pharmacologic treatments primarily address core symptoms with limited data on their impact on associated features. Evidence underscores the potential importance of three monoamines in ADHD presentation: DA, NE, and 5-HT.

This session covers efficacy and safety of a potential first-in-class NDSRI for ADHD treatment in children, adolescents, and adults. This agent is investigational and not FDA-approved.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Market Insights Webinar.

This webinar distills critical highlights to empower US managed care pharmacists. We’ll dive deep into real-world barriers beyond the clinic, exploring how SDOH, coverage gaps, care fragmentation, and side effect management influence treatment success. Gain evidence-based strategies and payer-centric tools to bridge these gaps, foster equitable access, and deliver measurable value in a competitive market.

Attendees will emerge equipped with forward-thinking insights to transform AD care delivery, from rethinking prior authorizations to leveraging real-world data for smarter decision-making.

An AMCP Webinar, presented by FormularyDecisions.

The anti-obesity medication market is undergoing rapid transformation, driven by innovative therapies, regulatory shifts, and evolving payer strategies. In response, managed care organizations and biopharma companies are navigating uncertainties as traditional coverage pathways are redefined. To navigate this dynamic environment, stakeholders must stay informed about the therapeutic landscape, emerging regulatory developments, and payer perspectives that will impact coverage and reimbursement.

This AMCP webinar will provide actionable insights into the current landscape for anti-obesity medications, including key market trends such as direct-to-consumer models. Attendees will have the opportunity to engage directly with Cencora’s topic experts during the live session, gaining real-time insights into the evolving market and implications for access.

An AMCP Webinar, presented by FormularyDecisions.

Managed care organizations and biopharmaceutical companies today are reimagining how to deliver sustained value and protect future innovation amid significant health policy changes. Key areas that will be covered in this upcoming AMCP webinar will include:

• Mapping the latest policy updates - ranging from manufacturer negotiations on drug pricing to government directives aimed at lowering health insurance costs.
• Forecasting potential future impacts for stakeholders in managed care pharmacy and the biopharmaceutical industry to empower informed decision-making and enhance patient support.
• Sharing real-world insights on how organizations are adapting to current and forecasted policy changes.